Immatics Biotechnologies Gmbh Stock Buy Hold or Sell Recommendation
| IMTXW Stock | USD 0.02 0 5.21% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding immatics biotechnologies GmbH is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell immatics biotechnologies GmbH given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for immatics biotechnologies GmbH, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Immatics Biotechnologies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Immatics and provide practical buy, sell, or hold advice based on investors' constraints. immatics biotechnologies GmbH. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Immatics |
Execute Immatics Biotechnologies Buy or Sell Advice
The Immatics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on immatics biotechnologies GmbH. Macroaxis does not own or have any residual interests in immatics biotechnologies GmbH or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immatics Biotechnologies' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immatics Biotechnologies Trading Alerts and Improvement Suggestions
| Immatics Biotechnologies generated a negative expected return over the last 90 days | |
| Immatics Biotechnologies has high historical volatility and very poor performance | |
| Immatics Biotechnologies has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 54 M. Net Loss for the year was (96.99 M) with loss before overhead, payroll, taxes, and interest of (23.99 M). |
Immatics Biotechnologies current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immatics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immatics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Immatics Biotechnologies Returns Distribution Density
The distribution of Immatics Biotechnologies' historical returns is an attempt to chart the uncertainty of Immatics Biotechnologies' future price movements. The chart of the probability distribution of Immatics Biotechnologies daily returns describes the distribution of returns around its average expected value. We use immatics biotechnologies GmbH price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immatics Biotechnologies returns is essential to provide solid investment advice for Immatics Biotechnologies.
| Mean Return | -2.34 | Value At Risk | -35.87 | Potential Upside | 32.98 | Standard Deviation | 21.91 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immatics Biotechnologies historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immatics Biotechnologies Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (15.9M) | 7.5M | (209.8M) | (31.4M) | (28.2M) | (29.7M) | |
| Change In Cash | 104.2M | (74.5M) | 15.5M | 70.0M | 63.0M | 66.1M | |
| Free Cash Flow | (93.1M) | (87.4M) | 93.9M | (12.7M) | (11.5M) | (10.9M) | |
| Depreciation | 4.4M | 5.3M | 7.0M | 7.2M | 8.3M | 5.5M | |
| Other Non Cash Items | 145.9M | 433K | (8.7M) | 5.7M | 5.1M | 4.8M | |
| Capital Expenditures | 7.5M | 5.7M | 6.2M | 31.0M | 35.6M | 37.4M | |
| Net Income | (229.6M) | (93.3M) | 37.5M | (97.0M) | (111.5M) | (117.1M) | |
| End Period Cash Flow | 207.5M | 133.0M | 148.5M | 218.5M | 251.2M | 155.9M |
Immatics Biotechnologies Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immatics Biotechnologies or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immatics Biotechnologies' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immatics stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -2.66 | |
β | Beta against Dow Jones | -2.86 | |
σ | Overall volatility | 24.06 | |
Ir | Information ratio | -0.1 |
Immatics Biotechnologies Volatility Alert
immatics biotechnologies GmbH is displaying above-average volatility over the selected time horizon. immatics biotechnologies GmbH is a penny stock. Although Immatics Biotechnologies may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in immatics biotechnologies GmbH. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Immatics instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Immatics Biotechnologies Fundamentals Vs Peers
Comparing Immatics Biotechnologies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immatics Biotechnologies' direct or indirect competition across all of the common fundamentals between Immatics Biotechnologies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immatics Biotechnologies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immatics Biotechnologies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Immatics Biotechnologies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immatics Biotechnologies to competition |
| Fundamentals | Immatics Biotechnologies | Peer Average |
| Return On Equity | -0.18 | -0.31 |
| Return On Asset | -0.0828 | -0.14 |
| Profit Margin | (0.48) % | (1.27) % |
| Operating Margin | 0.01 % | (5.51) % |
| Number Of Shares Shorted | 52.79 K | 4.71 M |
| Revenue | 54 M | 9.43 B |
| Gross Profit | (23.99 M) | 27.38 B |
| EBITDA | (88.93 M) | 3.9 B |
| Net Income | (96.99 M) | 570.98 M |
| Total Debt | 15.4 M | 5.32 B |
| Book Value Per Share | 3.71 X | 1.93 K |
| Cash Flow From Operations | 18.23 M | 971.22 M |
| Number Of Employees | 572 | 18.84 K |
| Beta | 0.83 | -0.15 |
| Market Capitalization | 673 M | 19.03 B |
| Total Asset | 509.96 M | 29.47 B |
| Retained Earnings | (597.29 M) | 9.33 B |
| Working Capital | 292.82 M | 1.48 B |
| Net Asset | 509.96 M |
Immatics Biotechnologies Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immatics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Immatics Biotechnologies Buy or Sell Advice
When is the right time to buy or sell immatics biotechnologies GmbH? Buying financial instruments such as Immatics Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Immatics Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Power Assets Thematic Idea Now
Power Assets
Large capitalization equities showing high long-term performance indicators and above average return expectations based on Macroaxis rating system. The Power Assets theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Power Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.